NCT02401035 - PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

June 18, 2021

Study Completion Date

June 18, 2021

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG

IV pantoprazole

Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight

Trial Locations (19)

11000

University Children's Clinic, Belgrade

21000

Institute for Child and Youth Health Care of Vojvodina, Novi Sad

44791

Katholisches Klinikum Bochum, Bochum

Zentralapotheke St. Josef-Hospital, Bochum

49006

Komunalne pidpryiemstvo Dnipropetrovskyi spetsializovanyi klinichnyi medychnyi tsentr materi, Dnipro

73013

"Komunalne nekomertsiine pidpryiemstvo Khersonska dytiacha oblasna klinichna likarnia", M. Kherson

75207

Children's Health Specialty Center Dallas Campus, Dallas

75235

Children's Medical Center Dallas, Dallas

76018

Komunalne nekomertsiine pidpryiemstvo Ivano-Frankivska oblasna dytiacha klinichna likarnia, Ivano-Frankivsk

78000

University clinical center of the Republic of Srpska, Banja Luka

84113

Primary Children's Hospital, Salt Lake City

C1426BOS

"Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich", CABA

0159

JSC Evex Medical Corporation, Tbilisi

LTD Imedi Clinic, Tbilisi

00165

Centro Trials - Dipartimento Pediatrico Universitario Ospedaliero Padiglione Salviati, Roma

IRCCS Ospedale Pediatrico Bambino Gesù, Roma

IRCCS-Ospedale Pediatrico Bambino Gesù Farmacia Ospedaliera, Roma

833 40

Narodny ustav detskych chorob, Bratislava

036 59

Univerzitna nemocnica Martin, Martin